Qfitlia (Fitusiran)

Qfitlia (fitusiran) is an antithrombin-directed small interfering ribonucleic acid used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or hemophilia B with or without factor VIII or IX inhibitors.

Recommended Dosage: The recommended starting dose of Fitusiran is 50 mg once subcutaneously every two months. Dosage and/or dosing interval can be adjusted if required, to maintain AT activity between 15% to 35%. Use of this therapeutic drug is recommended under the supervision of a healthcare professional (HCP) experienced in the treatment and management of hemophilia or bleeding disorders.

Measure AT activity before initiating this treatment. Do not initiate this treatment if AT activity is <60%. After initiating this treatment, patients may continue their prior clotting factor concentrates (CFC) or bypassing agent (BPA) prophylaxis for the first 1 week of treatment. Stop CFC or BPA prophylaxis no later than 1 week after the initial dose of Fitusiran.

• Treatment with Fitusiran 50 mg/0.5 mL or 20 mg/0.2 mL may increase the risk of thrombotic events (blood clots). Monitor patients for signs of thrombosis, especially during initiation and dose escalation. Immediate medical intervention is necessary if any implosive clotting symptoms are noticed.
• Fitusiran may cause liver damage. Liver function tests should be regularly monitored. If any signs of liver toxicity are observed (e.g. jaundice or increased liver enzymes) liver complication checks should be done immediately alongside discontinuing use.
• Fitusiran may lead to gallbladder issues such as inflammation or gallstones. Patients with a history of gallbladder issues need closer surveillance for symptoms including abdominal pain, nausea, and vomiting.
• Do not use Fitusiran during pregnancy unless the benefits outweigh the risks. It may be responsible for causing harm to the fetus. A pregnancy test is recommended before initiating treatment, and consider alternative therapies during pregnancy.
• The safety of Fitusiran during breastfeeding is not established. It’s unknown whether it gets into breast milk. Therefore it’s better to take caution and mothers make the call of whether to continue treatment or breastfeeding.
• Monitoring for bleeding is essential because Fitusiran has the potential to change the bleeding pattern of a patient. As with any bleeding problem, appropriate clotting factor therapy or surgical intervention should be provided expeditiously to the patient for correction of the complications.
• Contraception measures should be observed by both males and females of its reproductive potential while undergoing treatment with Fitusiran. Fertility is likely to be affected, and therefore, prospective measures should be taken to avoid pregnancy. Discuss contraceptive measures with the doctors before commencing therapy.

What documents are required to import QFITLIA to India?

QFITLIA (fitusiran) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is QFITLIA available in India?

QFITLIA (fitusiran injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Qfitlia in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

QFITLIA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of QFITLIA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Qfitlia 50 mg/0.5 mL injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source QFITLIA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Qfitlia®?

Fitusiran is a Generic Name for the trade name drug Qfitlia®.

What is the Manufacturer's Name of Qfitlia®?

Qfitlia® is manufactured by Genzyme Corporation.

Is Qfitlia approved by the FDA?

Yes, Qfitlia® is approved by the FDA. Date of first approval: March 28, 2025.

What is the dosage and form of Qfitlia® supplied?

Qfitlia is supplied in Injection: 50 mg/0.5 mL (100 mg/mL) in a single-dose prefilled pen and 20 mg/0.2 mL (100 mg/mL) in a single-dose vial for subcutaneous (SC) use.

What are the most common side effects of Qfitlia® injections?

The most common side effects of Qfitlia® injection are nasopharyngitis, viral infection, and bacterial infection.

How much does Qfitlia® injection cost in India?

Prices of Qfitlia injections may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Qfitlia 50 mg/0.5 mL injection cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Qfitlia® injections be available in SAARC countries?

Apart from Gulf countries, Qfitlia® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Qfitlia® injections in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Qfitlia® injections online in India?

Yes, one can buy Qfitlia 50 mg/0.5 mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Qfitlia® injections through legal channels.

What are the storage conditions of Qfitlia® injections?

Store 50 mg single-dose prefilled pen in the fridge (2°C to 8°C) or at room temperature (15°C to 30°C) for up to 3 months. For the 20 mg single-dose vial, store in the fridge or at room temperature. Do not shake, heat, or freeze.